Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Non-Deal Roadshow (October 2025)
21 slides from Rhythm Biosciences's roadshow presentation, Oct 10, 2025
Slide 1: Investor Roadshow Presentation
For personal use only Investor Roadshow Presentation OCTOBER 2025
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, rep
Slide 3: About Rhythm Biosciences
About Rhythm Biosciences We are committed to Early detection of cancer gives individuals the best possible opportunity For personal use only for favorable treatment outcomes. saving lives through the evaluation of cancer risk Addressing large under-served global markets worth >USD$50bn and heavily s
Slide 4: Corporate overview
Corporate overview CORPORATE SNAPSHOT SHARE PRICE CHART - ASX:RHY ASX Code RHY For personal use only 2 Share Price (9th October 2025) $0.089 1.5 Shares on Issue 329.5M Unlisted & Listed Options 52.5M 1 Market Capitalisation $28.07M 0.5 Cash in Bank (30 June 2025) $1.397M 0 Top 20 Shareholders 42.84%
Slide 5: Rhythm Bioscience: An attractive investment opportunity
Rhythm Bioscience: An attractive investment opportunity For personal use only Overview Growth Reasons to Invest Rhythm’s mission is to 1. Multi-product portfolio. detect cancer earlier and Rhythm is solving an reduce the burden of important clinical and 2. Addressing a significant TAM. cancer. We ar
Slide 6: Cancer is an increasing burden on global healthcare systems
Cancer is an increasing burden on global healthcare systems The role of cancer diagnostics remains critical to public health Estimated % rise in all cancers Estimated number of worldwide 2022 to 2050 prevalent cases in 5 years from 2022 For personal use only Males and Females, Age 0-85+ Incidence: 8
Slide 7: When diagnosed early, cancer can be successfully treated
When diagnosed early, cancer can be successfully treated Disease stage for colorectal cancer diagnosis is the key predictor of survival Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed in: For personal use only Missed detection of early-stage CRC results in poor surviva
Slide 8: Detecting cancer earlier and maintaining wellness
Detecting cancer earlier and maintaining wellness The power of the combination of the Rhythm capabilities and portfolio For personal use only Y N E U R Risk Assessment Disease Screening O J MONITORING AND Determination Minimally-invasive detection MINIMAL RESIDUAL T RISK ASSESSMENT DISEASE DETECTION
Slide 9: Multiomics: Proteins and Genes
Multiomics: Proteins and Genes Rhythm Biosciences has both a genomic and proteomic platform Cancer is a complex disease that is typified by For personal use only continuous change in cellular DNA, RNA (genome) and proteins (proteome). The genome and proteome contain some non- overlapping information
Slide 10: Our portfolio accesses different biology using similar products
Our portfolio accesses different biology using similar products Rhythm products are engineered for affordable quality For personal use only Risk Assessment Disease Screening Product Format Reagent kits/service Reagent kit/service Patient Sample Cheek swab Blood What we measure DNA variation and clin
Slide 11: About ColoSTAT
About ColoSTAT® For personal use only ColoSTAT® has been developed as an alternative blood-based solution for use in the detection of colorectal cancer A high quality, affordable blood- A subset of the higher risk population decline the use of stool-based tests based alternative for colorectal cance
Slide 12: ColoSTAT development history
ColoSTAT® development history An extensive clinical evaluation and careful design of a high-quality assay format For personal use only Assay Development: Biomarker Biomarker Clinical Pivotal Approval for Verification and Discovery Evaluation Study marketing Validation Candidate protein Biomarker eva
Slide 13: ColoSTAT FY26 commercial strategy
ColoSTAT ® FY26 commercial strategy Speed-to-market regulatory strategy and capital efficient commercial partnering For personal use only ColoSTAT® Assay Delivery Geographical Priorities Patient symptomatic Blood sample collected for bowel cancer consults GP at phlebotomy service Channel Strategy •
Slide 14: About Genetype
About Genetype For personal use only A cancer risk assessment platform designed for sporadic cancer risk A unique, integrated, Scope includes 6 cancers with validation data on 100,000s of individuals personalized cancer risk assessment platform leveraging clinical and Personalised using an individua
Slide 15: Genetype patient reports
Genetype patient reports For personal use only Absolute Risk over the defined time period For Breast Cancer: • 5-Year risk is relevant for decisions related to risk reducing drug therapy • Lifetime risk is relevant for qualification for MRI Risk compared to a reference population of the same age and
Slide 16: Genetype FY26 commercial strategy
Genetype FY26 commercial strategy Genetype FY26 Test Volumes Oncology Channel Portfolio Strategy For personal use only Focus • Health Care Volume from Enterprise Accounts • Breast* Professionals – B2B • Prostate • Strategic • Colorectal* partners/ • Ovarian Enterprise accounts - • Melanoma B2B2B Vol
Slide 17: Product launches and upgrades
Product launches and upgrades A diversified mix of development stages and underlying technologies will drive value For personal use only 2nd Gen CRC ColoSTAT® Lung cancer geneTypeTM Symptomatic geneTypeTM New Product Release Q1 Q2 Q3 Q4 2028 Ordering portal geneTypeTM update geneTypeTM update geneTy
Slide 18: Rhythm is targeting a significant global market
Rhythm is targeting a significant global market A global market of >0.5bn individuals potentially served by the Rhythm product platform. Genomic Platform: geneTypeTM Proteomic Platform: ColoSTAT® & Lung Cancer Screening For personal use only Unscreened high risk for Unscreened CRC Healthy CRC cancer
Slide 19: Our combined platforms supports a highly comprehensive product pipeline
Our combined platforms supports a highly comprehensive product pipeline For personal use only COLORECTAL PANCREATIC MELANOMA JO TIENT URNEY PROSTATE CERCIVAL OVARIAN A GASTRIC P > BREAST > LUNG MONITORING AND RISK MINIMAL RESIDUAL ASSESSMENT DISEASE DETECTION Surveillance PHARMA- COGENOMICS Risk Ass
Slide 20: Upcoming value inflection points
Upcoming value inflection points For personal use only PRODUCT ITEM DESCRIPTION COMPLETION DATE ColoSTAT® Final clinical validation Evaluation of final testing system Q3 CY 2025 geneTypeTM strategic geneTypeTM Establishment of key commercial partners Q3 CY 2025 partnerships geneTypeTM geneTypeTM men
Slide 21: Thank you!
For personal use only Thank you! david.atkins@rhythmbio.com www.rhythmbio.com
Rhythm Biosciences — Non-Deal Roadshow (October 2025) on 6ix